23andMe sees independent board directors quit en masse
23andMe's decline post-2021 IPO was due to reduced DNA kit interest and a significant ancestry data breach.
MAIN POINTS
- 23andMe went public in 2021 through a $3.5 billion merger.
- Declining interest in DNA kits impacted 23andMe's business.
- A data breach exposed ancestry information of 6.9 million users.
TAKEAWAYS
- Public market entry doesn't guarantee sustained success.
- Product demand fluctuations can significantly affect company performance.
- Data breaches can severely damage company reputation and trust.